Resources
13 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/7/2022 (updated 3/27/2024)
This session had three presenters who covered contingency management, prevention of stimulant use for children, and peer support.
Posted 5/24/2022 (updated 3/27/2024)
These contingency management resources include a statement and advisory opinions from the United States Department of Health and Human Services Office of Inspector General. Additionally, the Contingency Management factsheet provides an overview of the approach.
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 4/26/2021 (updated 4/10/2024)
A Protocol Using Empirically Supported Behavioral Treatments for People with Psychoactive Stimulant Use Disorders
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.